You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,670,244


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,670,244
Title:Oxysterol compounds and the hedgehog pathway
Abstract: This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention.
Inventor(s): Parhami; Farhad (Los Angeles, CA), Jung; Michael E. (Los Angeles, CA), Dwyer; Jennifer R. (Los Angeles, CA), Nguyen; Khanhlinh (Los Angeles, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:12/224,430
Patent Claims:1. A compound of the structure: ##STR00011##

2. A pharmaceutical composition, comprising a compound of the structure: ##STR00012## and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition comprising: (i) a compound of the structure: ##STR00013## (ii) at least one of 20(S)-hydroxycholesterol, 22(S)-hydroxycholesterol, or 22(R)-hydroxycholesterol; and a pharmaceutically acceptable carrier.

4. A method for stimulating a hedgehog (Hh) pathway in a cell or tissue in vitro, comprising contacting the cell or tissue with an effective amount of a compound of the structure: ##STR00014##

5. A method for treating a subject with a bone fracture, osteoporosis, osteoporitis, obesity, or osteoarthritis, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a compound of the structure: ##STR00015##

6. A method for indicating osteoblastic differentiation of a mammalian mesenchymal stem cell, comprising contacting the cell with an effective amount of a pharmaceutical composition comprising a compound of the structure: ##STR00016##

7. The method of claim 6, further comprising treating the mammalian mesenchymal cell with at least one secondary agent, selected from the group consisting of parathyroid hormone, sodium fluoride, insulin-like growth factor I (ILGF-I), insulin-like growth factor II (ILGF-II), transforming growth factor beta (TGF-.beta.), cytochrome P450 inhibitors, phospholipase activators, arachadonic acid, COX enzyme activators, osteogenic prostanoids, and ERK activators.

8. A method for stimulating a mammalian cell to express a level of a biological marker of osteoblastic differentiation which is greater than the level of the biological marker in an untreated cell, comprising exposing the mammalian cell to an effective amount of a pharmaceutical composition comprising a compound of the structure: ##STR00017## wherein the biological marker is alkaline phosphatase activity, calcium incorporation, mineralization and/or expression of osteocalcin mRNA.

9. The method of claim 8, wherein the mammalian cell is selected from the group consisting of a mesenchymal stem cell, an osteoprogenitor cell and a cell in a calvarial organ culture.

10. The method of claim 6, wherein the mammalian mesenchymal stem cell is a marrow stromal cell in a subject, and further comprising administering the pharmaceutical composition at a therapeutically effective dose in an effective dosage form at a selected interval to increase the number of osteoblasts present in bone tissue for treating the subject to increase the differentiation of marrow stromal cells into osteoblasts.

11. A method for treating a patient to induce bone formation comprising administering a pharmaceutical composition comprising a compound of the structure: ##STR00018## at a therapeutically effective dose in an effective dosage form at a selected interval to increase bone mass.

12. A method for treating osteoporosis in a patient, comprising administering a pharmaceutical composition comprising a compound of the structure: ##STR00019## at a therapeutically effective dose.

13. A method for treating a subject to induce bone formation comprising: harvesting mammalian mesenchymal stem cells; treating the mammalian mesenchymal cells with a compound of the structure: ##STR00020## wherein the compound induces the mesenchymal stem cells to express at least one cellular marker of osteoblastic differentiation; and administering the differentiated cells to the subject.

14. An implant for use in the human body comprising a substrate having a surface, wherein at least the surface of the implant includes a pharmaceutical composition comprising a compound of the structure: ##STR00021## in an amount sufficient to induce bone formation in the surrounding bone tissue.

15. The implant of claim 14, wherein the substrate is formed into the shape of a pin, screw, plate, or prosthetic joint.

16. A method for inhibiting a measurable amount of adipocyte differentiation of a mammalian mesenchymal stem cell, comprising contacting the mesenchymal stem cell with an effective amount of a pharmaceutical composition comprising a compound of the structure: ##STR00022##

17. A method for treating a subject in need of an increase in osteomorphogenesis, osteoproliferation, weight reduction, or the enhancement of cartilage production, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a compound of the structure: ##STR00023##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.